User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.

Primary tabs

Humblet, Yves [UCL]

The epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and differentiation and in the survival of healthy and cancerous cells. EGFR expression is a common feature of non-haematological malignancies and is associated with poor clinical prognosis. Cetuximab is an IgG(1) monoclonal antibody that blocks EGFR activation. It has efficacy alone, and in combination with irinotecan, in the treatment of metastatic colorectal cancer that has progressed on irinotecan-containing therapy. It has been approved for use in combination with irinotecan in both Switzerland and the US and as monotherapy in the US. Cetuximab also has efficacy in cancers of the head and neck and non-small cell lung cancer. Cetuximab is well-tolerated and does not exacerbate the side effects of co-administered cytotoxic chemotherapy.

  1. De Larco Joseph E., Todaro George J., Epithelioid and fibroblastic rat kidney cell clones: Epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation, 10.1002/jcp.1040940311
  2. Selvaggi G., Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer, 10.1093/annonc/mdh011
  3. O-charoenrat P, Rhys-Evans P.H, Archer D.J, Eccles S.A, C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors, 10.1016/s1368-8375(01)00029-x
  4. WIKSTRAND CJ, Cancer Res., 57, 4130 (1997)
  5. Paez J. G., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, 10.1126/science.1099314
  6. Lynch Thomas J., Bell Daphne W., Sordella Raffaella, Gurubhagavatula Sarada, Okimoto Ross A., Brannigan Brian W., Harris Patricia L., Haserlat Sara M., Supko Jeffrey G., Haluska Frank G., Louis David N., Christiani David C., Settleman Jeff, Haber Daniel A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib, 10.1056/nejmoa040938
  7. Herbst Roy S., Shin Dong M., Monoclonal antibodies to target epidermal growth factor receptor-positive tumors : A new paradigm for cancer therapy, 10.1002/cncr.10372
  8. GOLDSTEIN NI, Clin. Cancer Res., 1, 1311 (1995)
  9. FAN Z, Biol. Chem., 269, 27595 (1994)
  10. VANHOEFER U, Oncol, 22, 175 (2004)
  11. Cohen M. H., Williams G. A., Sridhara R., Chen G., McGuinn W. D., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., Baird A., Pazdur R., United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets, 10.1158/1078-0432.ccr-03-0564
  12. Kiyota Akihisa, Shintani Satoru, Mihara Mariko, Nakahara Yuuji, Ueyama Yoshiya, Matsumura Tomohiro, Tachikawa Tetsuhiko, Wong David T.W., Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates p27KIP1 and p15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines, 10.1159/000065726
  13. PENG D, Cancer Res, 56, 3666 (1996)
  14. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J, Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin., 10.1172/jci117871
  15. KARASHIMA T, Clin. Cancer Res., 8, 1253 (2002)
  16. PERROTTE P, Clin. Cancer Res., 5, 257 (1999)
  17. Naramura Mayumi, Gillies Stephen D., Mendelsohn John, Reisfeld Ralph A., Mueller Barbara M., Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma, 10.1007/bf01518458
  18. PREWETT MC, Clin. Cancer Res., 8, 994 (2002)
  19. CIARDIELLO F, Clin. Cancer Res., 5, 909 (1999)
  20. INOUE K, Clin. Cancer Res., 6, 4874 (2000)
  21. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller W. H., Mendelsohn J., Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies, 10.1093/jnci/85.16.1327
  22. BRUNS CJ, Clin. Cancer Res., 6, 1936 (2000)
  23. MILAS L, Clin. Cancer Res., 6, 701 (2000)
  24. Buchsbaum Donald J, Bonner James A, Grizzle William E, Stackhouse Murray A, Carpenter Mark, Hicklin Daniel J, Bohlen Peter, Raisch Kevin P, Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation, 10.1016/s0360-3016(02)03788-4
  25. Ye Dingwei, Mendelsohn John, Fan Zhen, Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225, 10.1038/sj.onc.1202319
  26. BASELGA J, /. Clin. Oncol, 18, 904 (2000)
  27. Parkin D. M., Pisani P., Ferlay J., Global cancer statistics, 10.3322/canjclin.49.1.33
  28. Cunningham D, Findlay M, The chemotherapy of colon cancer can no longer be ignored, 10.1016/0959-8049(93)90036-f
  29. SALTZ LB, Irinotecan Study Group. N Engl. I. Med., 343, 905 (2000)
  30. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, 10.1016/s0140-6736(00)02034-1
  31. Goldberg Richard M., Sargent Daniel J., Morton Roscoe F., Fuchs Charles S., Ramanathan Ramesh K., Williamson Stephen K., Findlay Brian P., Pitot Henry C., Alberts Steven R., A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, 10.1200/jco.2004.09.046
  32. Tournigand Christophe, André Thierry, Achille Emmanuel, Lledo Gérard, Flesh Michel, Mery-Mignard Dominique, Quinaux Emmanuel, Couteau Corinne, Buyse Marc, Ganem Gérard, Landi Bruno, Colin Philippe, Louvet Christophe, de Gramont Aimery, FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, 10.1200/jco.2004.05.113
  33. VANHOEFER U, I. Clin. Omni, 19, 1501 (2001)
  34. Saltz Leonard B., Meropol Neal J., Loehrer Patrick J., Needle Michael N., Kopit Justin, Mayer Robert J., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, 10.1200/jco.2004.10.182
  35. Iro Heinrich, Waldfahrer Frank, Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients, 10.1002/(sici)1097-0142(19981115)83:10<2201::aid-cncr20>3.0.co;2-7
  36. Pivot X., ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck, 10.1093/annonc/mdg295
  37. Kowalski L.P., Carvalho A.L., Natural history of untreated head and neck cancer, 10.1016/s0959-8049(00)00054-x
  38. Bourhis J., Rivera F., Mesia R., Awada A., Geoffrois L., Borel C., Duck L., Bessa E., Mueser M., Amellal N., 97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN), 10.1016/s1359-6349(03)90130-3
  39. Robert Francisco, Ezekiel Mark P., Spencer Sharon A., Meredith Ruby F., Bonner James A., Khazaeli M. B., Saleh Mansoor N., Carey Delicia, LoBuglio Albert F., Wheeler Richard H., Cooper Michael R., Waksal Harlan W., Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer, 10.1200/jco.2001.19.13.3234
  40. O'DWYER PJ, Semin. Omni, 29, 10 (2002)
  41. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern A.C., Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, 10.1046/j.1365-2133.2001.04226.x
Bibliographic reference Humblet, Yves. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.. In: Expert opinion on pharmacotherapy, Vol. 5, no. 7, p. 1621-33 (2004)
Permanent URL http://hdl.handle.net/2078.1/9885